Predictors of travel-related hepatitis A and B among native adult Danes: a nationwide case-control study.

Authors:
Address: Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark. ullanise@rm.dk
Journal:

Publication:

abstract

OBJECTIVES:

To assess journey length and other Predictors of travel-related acute hepatitis A (HAV) and B (HBV) virus infection among native Danes and determine the sensitivity and specificity of current pre-travel vaccination guidelines.

METHODS:

A nationwide case-control study was perfomed involving 60 Danes with HAV and 14 with HBV who acquired hepatitis in non-western countries from 2000 to 2010. Non-immune travellers from a nationwide survey (1188 HAV and 1709 HBV) served as controls.

RESULTS:

The odds ratios (ORs) for HAV and HBV increased with increasing journey length (p<0.0001). However, 90% of HAV and 62% of HBV cases travelled for less than 4 weeks, and the daily infection rate did not increase with journey length; rather, for HAV it decreased. Increasing age (p<0.0001) and journeys to Africa (OR 6.1 (3.2-11)) raised the risk of acute HAV. Travelling alone or with friends as compared to travelling with a partner/family (OR: 15 (3.2-134)) strongly predicted HBV risk. Danish vaccination guidelines had HAV/HBV sensitivities of 86%/31%, and specificities of 27%/95%, respectively. Incidence rates were 12.8 (HAV) and 10.2 (HBV) per 100,000 non-immune travel months, and acute disease severity affected HAV and HBV cases equally.

CONCLUSIONS:

These results may support revision of current pre-travel vaccination guidelines.

Related Articles
Hepatitis B risks and immunisation coverage amongst Australians travelling to southeast Asia and east Asia.
Travel Med Infect Dis. 2009
Hepatitis B risks and immunisation coverage amongst Australians travelling to southeast Asia and east Asia.
Leggat PA, Zwar NA, Hudson BJ, Travel Health Advisory Group, Australia. Travel Med Infect Dis. 2009 Nov; 7(6):344-9. Epub 2009 May 9.
Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy.
Am J Gastroenterol. 2001
Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy.
Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Am J Gastroenterol. 2001 Mar; 96(3):858-63.
Guidelines for the control of hepatitis A virus infection.
Commun Dis Public Health. 2001
Guidelines for the control of hepatitis A virus infection.
Crowcroft NS, Walsh B, Davison KL, Gungabissoon U, PHLS Advisory Committee on Vaccination and Immunisation. Commun Dis Public Health. 2001 Sep; 4(3):213-27.
Review Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand.
J Viral Hepat. 2000
Review Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand.
Pramoolsinsap C. J Viral Hepat. 2000 May; 7 Suppl 1:11-2.
Review Screening for hepatitis A and B antibodies in patients with chronic liver disease.
Am J Med. 2005
Review Screening for hepatitis A and B antibodies in patients with chronic liver disease.
Lau DT, Hewlett AT. Am J Med. 2005 Oct; 118 Suppl 10A:28S-33S.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.